Immunotherapy Advances, published by Oxford University Press, stands at the forefront of the rapidly evolving field of immunology and microbe interactions, focusing specifically on novel immunotherapeutic strategies and their clinical applications. Established in 2021, this peer-reviewed journal aims to disseminate high-quality research that contributes to the understanding and advancement of immunotherapeutic techniques, potentially transforming patient care in immunology. With a current Scopus rank of #140 out of 236 in the realm of Immunology, placing it in the 40th percentile, Immunotherapy Advances is positioned to be an integral resource for researchers, healthcare professionals, and students eager to stay updated with groundbreaking findings and methodologies. The journal is dedicated to fostering innovative discussions and collaborations, ensuring open access to vital research that influences treatment paradigms globally.

Welcome to the JOURNAL OF IMMUNOLOGY, a prestigious publication associated with the American Association of Immunologists and dedicated to advancing the field of immunology. With a rich history dating back to 1945, this journal is renowned for its high-impact research, evident in its notable 2023 Q1 rankings in both Immunology and Allergy, as well as its strong positions in Scopus rankings—Rank #68 in Immunology and Allergy and Rank #79 in Immunology and Microbiology. Although it operates on a subscription basis, its commitment to publishing cutting-edge studies ensures that it remains a vital resource for scientists, healthcare professionals, and students alike. As the journal continues to pave the way for innovative research and breakthroughs in immunological science, it facilitates a platform for dialogue and discovery among researchers and practitioners across the globe.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

IMMUNOLOGY is a premier journal published by Wiley that has been at the forefront of the field since its inception in 1958. With an impressive impact factor and classified in the Q1 quartile for both Immunology and Allergy as of 2023, this journal is highly regarded among researchers and professionals alike. It ranks 36th out of 233 in the Medicine/Immunology and Allergy category, and 40th out of 236 in the Immunology and Microbiology segment on Scopus, placing it firmly within the top percentile of its field. The journal is dedicated to publishing high-quality research that advances our understanding of immunological processes, bridging basic science with clinical applications. Although it does not operate under an open-access model, it offers conventional access options that remain integral to the dissemination of vital immunological research. With its broad scope and commitment to scholarly excellence, IMMUNOLOGY continues to serve as an essential resource for those seeking the latest advancements in immunology, fostering innovation and collaboration among scientists globally.

Autoimmune Diseases is a leading open-access journal published by Hindawi Ltd, dedicated to advancing the understanding and treatment of autoimmune disorders. Since its inception in 2010, this journal has provided a vital platform for researchers, clinicians, and students to share innovative findings and insights from the field of immunology. With an impressive Scopus ranking that highlights its relevance, particularly in the areas of Immunology and Microbiology and Immunology and Allergy, Autoimmune Diseases occupies a key position in the scientific discourse, ranking in the top quartiles across various categories. Researchers publishing in this journal benefit from a wide audience and high visibility, reflecting the increasing importance of understanding autoimmune diseases in today’s health landscape. Accessible to all, the journal promotes collaborative research and discussion, making it an essential resource for anyone dedicated to the study and management of autoimmune conditions.

JOURNAL OF CLINICAL IMMUNOLOGY, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the field of immunology, with an impressive standing as reflected in its Q1 ranking in both Immunology and Immunology and Allergy for 2023. With a history of publication dating back to 1981 and an E-ISSN of 1573-2592, this journal aims to disseminate cutting-edge research on diagnostic methods, therapeutic strategies, and understanding the mechanisms underlying immune responses. Its significant impact is underscored by its Scopus rankings, where it is placed in the top 15% of journals covering immunology and microbiology. The journal does not currently operate under an Open Access model, yet offers a robust platform for sharing essential findings that contribute to advancements in clinical immunology. As a resource for researchers, professionals, and students, the JOURNAL OF CLINICAL IMMUNOLOGY is pivotal in fostering dialogue and disseminating knowledge that enhances our understanding of immune-related diseases.

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

The Annual Review of Immunology, published by Annual Reviews, is a premier journal that has been contributing to the field of immunology since its establishment in 1983. With a strong reputation highlighted by its impressive impact factor and top-tier rankings—holding the Q1 category in both Immunology and Immunology and Allergy, alongside significant Scopus Rankings—this journal serves as an essential resource for researchers, professionals, and students alike. The Annual Review of Immunology covers the latest advancements and critical developments in the domain, fostering a better understanding of immune responses and disorders. Although it is not an open-access journal, it provides comprehensive reviews that synthesize emerging data and trends, making it indispensable for those at the forefront of immunological research. With volumes anticipated through 2024, it continues to set the standard for high-quality scholarly publications in the field.

INTERNATIONAL IMMUNOLOGY, published by OXFORD UNIV PRESS, stands out as a premier journal in the field of immunology, providing a vital platform for disseminating groundbreaking research and innovative developments within the discipline. With an impressive Q1 ranking in Immunology and Allergy, as well as in Medicine (miscellaneous), it consistently showcases high-impact studies that contribute to the advancement of immunological knowledge. The journal spans over three decades, from its inception in 1989 to its ongoing contributions as of 2024, thus solidifying its reputation in the scientific community. Researchers, professionals, and students will find valuable articles that delve into the complexities of immune responses, therapeutic interventions, and emerging immunological paradigms, ensuring INTERNATIONAL IMMUNOLOGY remains at the forefront of knowledge in the life sciences.

GENES AND IMMUNITY, published by SpringerNature, is a leading scholarly journal dedicated to advancing the field of genetics and immunology. With an impressive impact factor and a distinguished ranking in the Q1 quartile of both Genetics and Immunology disciplines for 2023, this journal serves as a pivotal platform for researchers and professionals looking to explore the intricate relationships between genetic factors and immune responses. Established in 1999 and continuously published until 2024, it features high-quality peer-reviewed research articles, reviews, and commentary that address critical issues and recent advancements in the field. The journal adheres to rigorous academic standards, evidenced by its strong Scopus rankings, making it a valuable resource for students, researchers, and practitioners alike who are seeking to deepen their understanding of genetics' role in immunity. For those looking to keep abreast of cutting-edge insights, GENES AND IMMUNITY is an essential read.